Kasten, Inc. (KAST) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Kasten, Inc. (KAST) trades at $4.00 with AI Score 51/100 (Grade B). Kasten, Inc. , operating as DAKOTA Life Sciences, focuses on acquiring, developing, and commercializing pharmaceuticals. Market cap: $165M, Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for KAST: KAST does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KAST against Financial Services peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
KAST: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Kasten, Inc. (KAST) Financial Services Profile
Kasten, Inc., under the DAKOTA Life Sciences brand, is a biopharmaceutical company focused on acquiring and developing affordable pharmaceuticals for antimicrobial resistance. Operating in the financial services sector as a shell company, Kasten aims to deliver solutions in hospital and community settings, distinguishing itself through targeted pharmaceutical acquisitions.
What Is the Investment Thesis for KAST?
Kasten, Inc., operating as DAKOTA Life Sciences, presents a high-risk, high-reward investment profile. With a market capitalization of $165M and a P/E ratio of 6107.33, the company's valuation is highly speculative. A key value driver is its focus on acquiring and developing pharmaceuticals targeting antimicrobial resistance, addressing a critical global health need. Growth catalysts include successful acquisition of promising drug candidates and subsequent commercialization. However, the company's OTC listing and high beta of 6.22 indicate significant volatility. The company's small profit margin of 2.6% and lack of dividend payments further underscore the speculative nature of this investment. Investors should carefully consider the risks associated with OTC-listed companies and the challenges inherent in the biopharmaceutical industry.
Based on FMP financials and quantitative analysis
KAST Key Highlights
Market capitalization of $165M indicates a micro-cap company with potential for high growth but also significant risk.
- P/E ratio of 6107.33 suggests the company's earnings are minimal relative to its stock price, reflecting high investor expectations or overvaluation.
- Gross margin of 29.5% indicates the company retains a portion of revenue after accounting for the cost of goods sold, but this needs to cover operating expenses.
- Beta of 6.22 signifies the stock is highly volatile compared to the market, implying substantial price swings.
- Profit margin of 2.6% demonstrates limited profitability, highlighting the need for improved operational efficiency or revenue growth.
Who Are KAST's Competitors?
KAST is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| APXI APx Acquisition Corp. I | $11.90 | +4.39% | $118M | 49 |
| CNBL Citizens National Bancshares of Bossier, Inc. | $25.00 | +0.00% | $165M | 50 |
| DSAQ Direct Selling Acquisition Corp. | $11.69 | +0.00% | $99.0M | 44 |
| ERPRF European Reliance General Insurance Company S.A. | $5.20 | +0.00% | $164M | 46 |
| FMAC FirstMark Horizon Acquisition Corp. | $10.06 | +0.20% | $159M | 64 |
| BLRKU Bluerock Acquisition Corp. | $10.48 | +2.44% | $181M | 67 |
| SOCA Solarius Capital Acquisition Corp. | $10.33 | -0.19% | $183M | 65 |
| BREZ Breeze Holdings Acquisition Corp. | $10.00 | +0.20% | $144M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KAST's Key Strengths?
Focus on a critical healthcare need: antimicrobial resistance.
- Potential for high growth in a niche market.
- Acquisition-based business model allows for rapid expansion.
- Commitment to affordable pricing.
What Are KAST's Weaknesses?
Small market capitalization and limited financial resources.
- High dependence on successful acquisitions.
- OTC listing increases risk and volatility.
- Limited product portfolio.
What Could Drive KAST Stock Higher?
Successful acquisition of new pharmaceutical assets to expand product pipeline.
- Positive results from clinical trials of drug candidates targeting antimicrobial resistance.
- Regulatory approval of new pharmaceutical products by relevant authorities.
- Strategic partnerships with larger pharmaceutical companies to accelerate development and commercialization.
- Expansion into new geographic markets with high prevalence of antimicrobial resistance.
What Are the Key Risks for KAST?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to successfully acquire and develop new pharmaceutical assets.
- Regulatory delays or rejection of drug candidates.
- Intense competition from larger pharmaceutical companies.
- Limited financial resources and high dependence on external funding.
- Volatility associated with OTC listing and speculative valuation.
What Are the Growth Opportunities for KAST?
- Acquisition of Promising Drug Candidates: Kasten, Inc. can drive growth by acquiring rights to promising pharmaceutical compounds targeting antimicrobial resistance. Successful acquisitions, followed by effective development and commercialization, could significantly boost Kasten's revenue and market share. The timeline for realizing this growth depends on the stage of development of the acquired compounds and the regulatory approval process.
- Strategic Partnerships and Collaborations: Forming strategic alliances with larger pharmaceutical companies or research institutions can provide Kasten, Inc. with access to additional resources, expertise, and funding. Collaborations can accelerate the development and commercialization of its pharmaceutical products. The global pharmaceutical partnering market is estimated to be worth billions of dollars annually. These partnerships can provide Kasten with a competitive advantage and reduce the financial risk associated with drug development. The timeline for realizing the benefits of these partnerships depends on the specific agreements and the progress of collaborative projects.
- Expansion into New Geographic Markets: Kasten, Inc. can expand its market reach by entering new geographic regions with a high prevalence of antimicrobial resistance. Emerging markets, in particular, offer significant growth opportunities due to their large populations and increasing healthcare spending. Successful expansion into new markets requires careful planning, regulatory compliance, and effective distribution strategies.
- Development of Novel Drug Delivery Systems: Investing in the development of innovative drug delivery systems can enhance the efficacy and patient compliance of Kasten's pharmaceutical products. Novel drug delivery technologies, such as targeted drug delivery and sustained-release formulations, can improve therapeutic outcomes and reduce side effects. This can provide a competitive advantage and differentiate Kasten's products from those of its competitors. The timeline for realizing this growth depends on the success of research and development efforts and the regulatory approval process.
- Focus on Orphan Drug Designations: Pursuing orphan drug designations for its pharmaceutical products can provide Kasten, Inc. with significant financial incentives and market exclusivity. Orphan drug designations are granted to drugs that treat rare diseases or conditions, providing companies with tax credits, reduced regulatory fees, and extended market exclusivity. This can provide a significant competitive advantage and enhance the profitability of Kasten's pharmaceutical products. The timeline for realizing these benefits depends on the successful completion of clinical trials and the granting of orphan drug designations by regulatory agencies.
What Threats Does KAST Face?
- Intense competition from larger pharmaceutical companies.
- Regulatory hurdles and lengthy approval processes.
- Risk of unsuccessful acquisitions.
- Changes in healthcare policies and reimbursement rates.
What Are KAST's Competitive Advantages?
- Focus on antimicrobial resistance provides a niche market.
- Acquisition and development of pharmaceutical assets creates intellectual property.
- Affordable pricing strategy can attract price-sensitive customers.
- Established relationships with hospitals and community healthcare providers.
What Does KAST Do?
Kasten, Inc., conducting business as DAKOTA Life Sciences, was established in 1986 and is headquartered in Sioux Falls, South Dakota. The company operates within the biopharmaceutical sector, focusing on the acquisition, development, and commercialization of pharmaceutical products. Its primary mission is to address serious conditions that arise in both hospital and community environments. DAKOTA Life Sciences is particularly focused on providing affordable solutions to individuals affected by antimicrobial resistance, a growing global health concern. The company's strategy involves identifying and acquiring promising pharmaceutical assets, developing them further, and bringing them to market at accessible price points. This approach aims to fill a critical need for affordable medications in the face of increasing drug resistance. Kasten, Inc., through DAKOTA Life Sciences, aims to establish itself as a key player in delivering cost-effective pharmaceutical solutions, particularly in the realm of antimicrobial resistance, serving both hospital and community healthcare settings.
What Products and Services Does KAST Offer?
- Acquires pharmaceutical assets focused on addressing antimicrobial resistance.
- Develops acquired pharmaceutical compounds for commercialization.
- Commercializes pharmaceuticals in hospital and community settings.
- Focuses on providing affordable pharmaceutical solutions.
- Targets serious conditions arising in hospital and community settings.
- Delivers solutions to people affected by antimicrobial resistance.
How Does KAST Make Money?
- Acquire pharmaceutical assets or rights to drug candidates.
- Develop and formulate these assets into marketable pharmaceutical products.
- Commercialize and distribute these products through hospitals and community healthcare providers.
- Generate revenue through the sale of pharmaceutical products.
What Industry Does KAST Operate In?
Kasten, Inc. operates within the biopharmaceutical industry, specifically targeting antimicrobial resistance. This sector is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Kasten's competitors include companies like APXI, BFGX, CNBL, DSAQ, and ERPRF, which are also navigating the complexities of drug development and commercialization. Kasten's success hinges on its ability to efficiently acquire, develop, and commercialize pharmaceuticals in a cost-effective manner.
Who Are KAST's Key Customers?
- Hospitals and healthcare systems.
- Community healthcare providers and clinics.
- Patients requiring treatment for antimicrobial-resistant infections.
- Pharmacies and distributors.
Kasten, Inc. (KAST) Valuation Context
Valued at $165M, KAST is classified as a micro-cap stock. Relative to its peer group, KAST's quantitative score of 51/100 is roughly in line with the peer average of 51/100.
KAST Revenue & Earnings Trend
In Q4 2024, KAST generated $251K in top-line revenue, marking a sequential increase of 591.8%. The company recorded a net loss of $590, with diluted EPS of $-0.00. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Financial Services company. Across the four most recent quarters, KAST averaged $-0.00 in diluted EPS.
Company Profile
Kasten, Inc. operates in the Shell Companies industry within the Financial Services sector. It is headquartered in Sioux Falls, US. The company is led by CEO Jingwei Zhang. KAST has traded publicly since 1995.
Key Financial Metrics
Return on assets is -26.4%, showing how much profit it generates from its asset base. A current ratio of 0.15 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Kasten, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
KAST Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Focus on a critical healthcare need: antimicrobial resistance.
- Potential for high growth in a niche market.
- Acquisition-based business model allows for rapid expansion.
- Commitment to affordable pricing.
Bear Case
- Small market capitalization and limited financial resources.
- High dependence on successful acquisitions.
- OTC listing increases risk and volatility.
- Limited product portfolio.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2024 | $250,610 | -$590 | -$0.0000 |
| Q3 2024 | $36,224 | $8,000 | $0.0002 |
| Q2 2024 | $2,819 | $11,704 | $0.0003 |
| Q1 2024 | $16,536 | -$82,376 | -$0.0020 |
Based on FMP financials and quantitative analysis
KAST Latest News
No recent news available for KAST.
KAST Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KAST.
Price Targets
Wall Street price target analysis for KAST.
KAST MoonshotScore
What does this score mean?
The MoonshotScore rates KAST 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry Shell CompaniesLeadership: Jingwei Zhang
CEO
Jingwei Zhang serves as the Chief Executive Officer of Kasten, Inc. While specific details regarding Zhang's prior experience and educational background are not available in the provided data, it is understood that he leads the company's strategic direction and operational execution. His role involves overseeing the acquisition, development, and commercialization of pharmaceutical products, as well as managing the company's financial performance and investor relations. Further information on his background would be needed to provide a more detailed profile.
Track Record: Due to limited information, Jingwei Zhang's specific achievements and strategic decisions as CEO of Kasten, Inc. cannot be fully assessed. However, as CEO, he is responsible for guiding the company's focus on antimicrobial resistance and its efforts to deliver affordable pharmaceutical solutions. The company's performance and milestones under his leadership would be key indicators of his track record. Further data is needed to provide a comprehensive evaluation.
KAST OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Kasten, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and increased volatility compared to exchange-listed stocks.
- OTC Tier: OTC Other
- Limited regulatory oversight compared to exchange-listed companies.
- Potential for lack of transparency and limited financial information.
- Higher price volatility and wider bid-ask spreads.
- Risk of fraud or manipulation due to less stringent listing requirements.
- Lower liquidity, making it difficult to buy or sell shares.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- Company has been in operation since 1986.
- Focus on addressing a critical healthcare need: antimicrobial resistance.
- Commitment to providing affordable pharmaceutical solutions.
- Operation as DAKOTA Life Sciences suggests a focus on healthcare.
- Company headquarters are located in Sioux Falls, South Dakota.
What Investors Ask About Kasten, Inc. (KAST) — Financial Services
What does the AI Score mean for KAST?
KAST holds an AI Score of 51/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Kasten, Inc., operating as DAKOTA Life Sciences, focuses on acquiring, developing, and commercializing pharmaceuticals. The company targets antimicrobial resistance solutions in hospital …
What does Kasten, Inc. do?
Kasten, Inc., operating as DAKOTA Life Sciences, is a biopharmaceutical company focused on acquiring, developing, and commercializing pharmaceutical products. The company targets serious conditions arising in hospital and community settings, with a specific focus on providing affordable solutions to individuals affected by antimicrobial resistance.
What do analysts say about KAST stock?
Given Kasten, Inc.'s status as an OTC-listed company with a small market capitalization, comprehensive analyst coverage may be limited. Key valuation metrics, such as the high P/E ratio of 6107.33, suggest a speculative valuation. Growth considerations include the successful acquisition and development of new pharmaceutical assets, as well as the company's ability to navigate the regulatory landscape.
What are the main risks for KAST?
Kasten, Inc. faces several risks, including the challenges inherent in the biopharmaceutical industry, such as lengthy regulatory approval processes and the potential for clinical trial failures. As an OTC-listed company, Kasten is subject to increased volatility and limited liquidity. The company's small market capitalization and limited financial resources make it vulnerable to market fluctuations and funding constraints.
What are the key factors to evaluate for KAST?
Kasten, Inc. (KAST) holds an AI score of 51/100 (moderate). Kasten, Inc., operating as DAKOTA Life Sciences, presents a high-risk, high-reward investment profile. Not financial advice.
How frequently does KAST data refresh on this page?
KAST's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven KAST's recent stock price performance?
Kasten, Inc. (KAST) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on a critical healthcare need: antimicrobial resistance. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KAST overvalued or undervalued right now?
Kasten, Inc. (KAST) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research KAST before investing?
Before investing in Kasten, Inc. (KAST), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO background and track record.
- OTC market investments are inherently risky.
- Financial data is limited, requiring further due diligence.